[go: up one dir, main page]

SU1261665A1 - Method of treatment of thymomegalia of children - Google Patents

Method of treatment of thymomegalia of children Download PDF

Info

Publication number
SU1261665A1
SU1261665A1 SU843814204A SU3814204A SU1261665A1 SU 1261665 A1 SU1261665 A1 SU 1261665A1 SU 843814204 A SU843814204 A SU 843814204A SU 3814204 A SU3814204 A SU 3814204A SU 1261665 A1 SU1261665 A1 SU 1261665A1
Authority
SU
USSR - Soviet Union
Prior art keywords
thymalin
treatment
children
per
thymomegalia
Prior art date
Application number
SU843814204A
Other languages
Russian (ru)
Inventor
Анатолий Иванович Кожемяка
Едил Тайтолеуович Дадамбаев
Валентин Виссарионович Басилайшвили
Владимир Хацкелевич Хавинсон
Вячеслав Григорьевич Морозов
Анна Кириловна Солодун
Василий Петрович Кандыба
Original Assignee
Харьковский Медицинский Институт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Харьковский Медицинский Институт filed Critical Харьковский Медицинский Институт
Priority to SU843814204A priority Critical patent/SU1261665A1/en
Application granted granted Critical
Publication of SU1261665A1 publication Critical patent/SU1261665A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Изобретение относитс  к педиатрии. Цель изобретени  - снижение побочных осложнений. Больным дет м с тимомегалией тималин назначают из расчета 0,1 мг на 1 кг массы тела 1 раз в день внутримышечно. Курс лечени  тималином составл ет 3-7 дней в зависимости от степени выраженности тимомегалии и сопутствующего заболевани .This invention relates to pediatrics. The purpose of the invention is to reduce side effects. Thymalin is prescribed at a rate of 0.1 mg per 1 kg of body weight 1 time a day intramuscularly for patients with timomegaly. The treatment with thymalin is 3-7 days, depending on the severity of thymomegaly and concomitant disease.

Description

tsDtsD

о:about:

О5 05 СПO5 05 SP

Изобретение относитс  к медицине, а именно к педиатрии.FIELD OF THE INVENTION The invention relates to medicine, namely to pediatrics.

Целью изобретени   вл етс  снижение побочных осложнений.The aim of the invention is to reduce side effects.

Способ осуществл етс  следующим образом .The method is carried out as follows.

Больным дет м с тимомегалией тималин назначают из расчета 0,1 мг на кг массы тела 1 раз в день внутримыщечно. Курс лечени  тималином составл ет 3-7 дней в зависимости от степени выраженности тимомегалии и сопутствующего заболевани .Thymalin is prescribed at a rate of 0.1 mg per kg of body weight 1 time per day intramuscularly for patients with timomegaly. The treatment with thymalin is 3-7 days, depending on the severity of thymomegaly and concomitant disease.

Пример. Больному ребенку 5 мес цев жизни с диагнозом: бронхопневмони  очагова  с бронхообструктивным синдромом, острое течение, тимомегали  I степени производ т иммунологическое и рентгенологическое исследование до и после курса лечени . Вместе с антибактериальной терапией назначают тималин из расчета 0,1 мг на кг массы внутримышечно в течение 4-х дней.Example. A 5 month old patient with a diagnosis of the patient: bronchopneumonia foci with broncho-obstructive syndrome, acute course, first degree timomegali, perform an immunological and X-ray examination before and after the course of treatment. Together with antibacterial therapy, thymalin is prescribed at the rate of 0.1 mg per kg intramuscular mass for 4 days.

После курса лечени  тималином отмечают значительное нарастание количестваAfter treatment with thymalin, a significant increase in the number of

Т-активных и В-лимфоцитов и увеличение содержани  иммуноглобулинов класса G и А. На 14-й день наступило клиническое выздоровление и ребенок выписан из стационара .T-active and B-lymphocytes and an increase in the content of immunoglobulins class G and A. On the 14th day, a clinical recovery occurred and the child was discharged from the hospital.

Доза тималина, равна  0,1 мг на кг массы ребенка вызывала увеличение Т-активных клеток в 4,5 раза. Тогда как доза, равна  0,2 мг на кг массы вызывает увеличение этих клеток в 2,5 раза.The dose of thymalin, equal to 0.1 mg per kg of the child’s mass, caused an increase in T-active cells by 4.5 times. While the dose of 0.2 mg per kg of mass causes an increase in these cells by 2.5 times.

Таким образом, лимфоциты больных детей с тимомегалией про вл ют большую чувствительность к дозе 0,1 мг/кг.Thus, the lymphocytes of sick children with thymomegaly show greater sensitivity to a dose of 0.1 mg / kg.

Claims (1)

Формула изобретени Invention Formula Способ лечени  тимомегалии у детей путем введени  лекарственных средств, отличающийс  тем, что, с целью снижени  побочных осложнений, в качестве лекарственных средств ввод т тималин внутримышечно в дозе 0,1 мг/кг массы в день в течение 3-7 дней.A method of treating thymomegaly in children by administering drugs, characterized in that, in order to reduce the side effects, thymalin is administered intramuscularly as a drug at a dose of 0.1 mg / kg of body weight per day for 3-7 days.
SU843814204A 1984-11-19 1984-11-19 Method of treatment of thymomegalia of children SU1261665A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SU843814204A SU1261665A1 (en) 1984-11-19 1984-11-19 Method of treatment of thymomegalia of children

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SU843814204A SU1261665A1 (en) 1984-11-19 1984-11-19 Method of treatment of thymomegalia of children

Publications (1)

Publication Number Publication Date
SU1261665A1 true SU1261665A1 (en) 1986-10-07

Family

ID=21147410

Family Applications (1)

Application Number Title Priority Date Filing Date
SU843814204A SU1261665A1 (en) 1984-11-19 1984-11-19 Method of treatment of thymomegalia of children

Country Status (1)

Country Link
SU (1) SU1261665A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811399A (en) * 1988-12-14 1998-09-22 Cytran, Inc. Pharmaceutical dipeptide compositions and methods of use thereof: immunodepressants
US6368788B1 (en) 1987-12-30 2002-04-09 Cytran, Inc. Method of treating complications in immunodepressed states resulting from HIV infection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Гусейнов Ш. Т. Клинико-метаболические особенности и лечени гиперплазии вилочковой железы в сочетании с пневмонией у детей:. Автореф. дне., 1983, с. 1 -10. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6368788B1 (en) 1987-12-30 2002-04-09 Cytran, Inc. Method of treating complications in immunodepressed states resulting from HIV infection
US6777195B2 (en) 1987-12-30 2004-08-17 Cytran, Inc. Pharmaceutical dipeptide compositions and methods of use thereof: immunostimulants
US5811399A (en) * 1988-12-14 1998-09-22 Cytran, Inc. Pharmaceutical dipeptide compositions and methods of use thereof: immunodepressants

Similar Documents

Publication Publication Date Title
Craft Torsade de pointes after astemizole overdose
US4435449A (en) Treatment of minimal brain dysfunction (MBD)
Saito et al. Acute disseminated encephalomyelitis after influenza vaccination
Bunnag et al. Studies on the chemotherapy of human opisthorchiasis in Thailand: I. Clinical trial of praziquantel
Kataoka et al. Intermittent high-dose vitamin C therapy in patients with HTLV-I associated myelopathy.
Barnes et al. Dihydrocodeine narcosis in renal failure
SU1261665A1 (en) Method of treatment of thymomegalia of children
Shaklai et al. Metoclopramide and cardiac arrhythmia
JPH08512311A (en) Arsenic medicine for treating chronic fatigue syndrome
HOWARD et al. Effects of pituitary adrenocorticotropic hormone (ACTH) on the hypersensitive state
Grover et al. Recovery following cranial nerve dysfunction and muscle weakness in infancy
Sharma et al. Clinical evaluation of the anorexic activity and safety of 42-548 in children: Report of a clinical trial
Alajem et al. Severe imipramine poisoning in an infant
Saúl et al. Treatment of multiple viral warts with levamisole
Mushinski et al. Guillain‐Barre syndrome associated with ulceroglandular tularemia
SU1105202A1 (en) Method of treatment of gastric ulcer and duodenal ulcer
RU2196576C1 (en) Method of treatment of patients with hemorrhagic fever and renal syndrome
Linder et al. Treatment of neonatal immune thrombocytopenia with high dose intravenous γ-globulin
SU1232263A1 (en) Method of treatment of pneumonia of children at early age
SU1097334A1 (en) Method of treatment ischemia heart diseases
SU1232257A1 (en) Method of treatment of pulmonary tuberculosis
SU1136798A1 (en) Method of treatment of hyperactive behavour
Biagi et al. Antiamoebic action of etophamide in children
SU921578A1 (en) Method of curing child hepatitis
SU1132946A1 (en) Method of treatment of immune insufficiency